IMMUNOPATHOLOGY AND INFECTIOUS DISEASES

Human Polyomavirus Receptor Distribution in Brain Parenchyma Contrasts with Receptor Distribution in Kidney and Choroid Plexus

Sheila A. Haley,^{*} Bethany A. O'Hara,^{*} Christian D.S. Nelson,^{*} Frances L.P. Brittingham,^{*} Kammi J. Henriksen,[†] Edward G. Stopa,[†] and Walter J. Atwood^{*}

From the Departments of Molecular Biology, Cell Biology and Biochemistry^{*} and Pathology and Laboratory Medicine,[†] Warren Alpert Medical School, Brown University, Providence, Rhode Island

Accepted for publication
April 14, 2015.

Address correspondence to
Walter J. Atwood, Ph.D.,
Department of Molecular
Biology, Cell Biology and
Biochemistry, Brown Univer-
sity, 70 Ship St., Providence,
RI 02903. E-mail: walter_atwood@brown.edu.

The human polyomavirus, JCPyV, is the causative agent of progressive multifocal leukoencephalopathy, a rare demyelinating disease that occurs in the setting of prolonged immunosuppression. After initial asymptomatic infection, the virus establishes lifelong persistence in the kidney and possibly other extraneural sites. In rare instances, the virus traffics to the central nervous system, where oligodendrocytes, astrocytes, and glial precursors are susceptible to lytic infection, resulting in progressive multifocal leukoencephalopathy. The mechanisms by which the virus traffics to the central nervous system from peripheral sites remain unknown. Lactoseries tetrasaccharide c (LSTc), a pentasaccharide containing a terminal $\alpha 2,6$ -linked sialic acid, is the major attachment receptor for polyomavirus. In addition to LSTc, type 2 serotonin receptors are required for facilitating virus entry into susceptible cells. We studied the distribution of virus receptors in kidney and brain using lectins, antibodies, and labeled virus. The distribution of LSTc, serotonin receptors, and virus binding sites overlapped in kidney and in the choroid plexus. In brain parenchyma, serotonin receptors were expressed on oligodendrocytes and astrocytes, but these cells were negative for LSTc and did not bind virus. LSTc was instead found on microglia and vascular endothelium, to which virus bound abundantly. Receptor distribution was not changed in the brains of patients with progressive multifocal leukoencephalopathy. Virus infection of oligodendrocytes and astrocytes during disease progression is LSTc independent. (*Am J Pathol* 2015; 185: 2246–2258; <http://dx.doi.org/10.1016/j.ajpath.2015.04.003>)

The human polyomavirus (JCPyV) is the causative agent of progressive multifocal leukoencephalopathy (PML), a rapidly progressing, often fatal neurodegenerative disease. Although PML is rare, JCPyV infection is widespread, infecting approximately 50% to 80% of the healthy adult population.^{1,2} As the initial infection is asymptomatic, the mode of JCPyV transmission is unknown. The virus establishes a persistent infection in the kidney and urinary tract of immunocompetent hosts,³ and about 20% of these infected individuals shed virus in their urine.⁴ JCPyV DNA has also been detected in other tissues, including B lymphocytes in the bone marrow, tonsillar stromal cells, lungs, spleen, and brain,^{5–13} suggesting additional sites of viral persistence. The route of viral transmission from the initial site(s) of infection and latency to the central nervous system (CNS), the main site of pathogenesis, is not clearly understood.

Under conditions of immunosuppression, JCPyV infects and destroys the myelin-producing oligodendrocytes, resulting in demyelination, which is the hallmark of this fatal disease; to a

Supported by NIH grants R01NS043097 (W.J.A.) and P01NS065719 (W.J.A.). Core facilities at Brown are supported by NIH grant P30GM103410 (W.J.A.). Progressive multifocal leukoencephalopathy brain tissues were obtained via funding through the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke (the Manhattan HIV Brain Bank: U01MH083501 and R24MH59724; the Texas NeuroAIDS Research Center: U01MH083507 and R24NS45491; and the California NeuroAIDS Tissue Network: U01MH083506 and R24MH59745).

The content of this work is solely the responsibility of the authors and does not necessarily represent the official view of the National NeuroAIDS Tissue Consortium or the NIH.

Disclosures: None declared.

Current address of K.J.H., Department of Pathology, University of Chicago Pritzker School of Medicine, Chicago, IL.

lesser degree, astrocytes and neurons are infected as well.^{14,15} When PML was first described, it was a rare disease that primarily affected patients with B-cell lymphoproliferative disorders.^{16,17} During the AIDS pandemic, the prevalence of PML in patients rose significantly, with 3% to 5% of HIV/AIDS patients developing PML.^{18,19} With the advent of combined antiretroviral therapy, the number of HIV/AIDS patients with PML has declined, although it has decreased less significantly than that of other opportunistic infections.²⁰ While the occurrence of PML historically has been linked to HIV/AIDS, recently the rate of PML has risen again with the introduction of immunomodulatory therapy for autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, psoriasis, and Crohn disease.^{21–25} PML has been reported to occur in patients receiving treatment with drugs including the monoclonal antibodies natalizumab, efalizumab, and rituximab.^{22,26} One action of these therapies is to inhibit leukocyte migration into the CNS, suggesting that a key to JCPyV pathogenesis in the brain is the suppression of cells that normally perform immune surveillance. In addition to PML, JCPyV causes other diseases of the CNS, including JCPyV granule cell neuronopathy²⁷ and JCPyV encephalopathy,²⁸ and has been associated with isolated cases of JCPyV-associated nephropathy in kidney transplant recipients.^{29–32}

JCPyV has a circular, double-stranded DNA genome that is enclosed by a nonenveloped, icosahedral capsid, which is composed of three proteins, viral proteins (VP)-1, -2, and -3.³³ VP1 is the main component of the capsid and is the primary means by which the virus engages receptors to initiate infection of host cells.

JCPyV requires at least two known functional receptors for attachment and subsequent entry. Previous *in vitro* experiments have demonstrated that the virus initially binds to an α 2,6 sialic acid on the cell surface.^{34–36} Crystallographic and functional studies with VP1 demonstrated that JCPyV VP1 binds to the host cell via the α 2,6-linked glycan lactoseries tetrasaccharide c (LSTc).³⁷ Although LSTc recognition is required for JCPyV attachment, it is not sufficient for viral infection. In addition to engaging LSTc on the cell surface, JCPyV entry requires the presence of a serotonin (5-HT)-2 receptor family member. Virus internalization in a nonpermissive cell line was markedly enhanced when the cell line was transfected with any of the three 5-HT₂ receptor family subtypes, 5-HT_{2A}, 5-HT_{2B}, or 5-HT_{2C}, and shown to act early in the virus life cycle by facilitating virus entry.^{38,39} JCPyV infection is blocked by antibodies to 5-HT₂s and other specific inhibitors of these receptors.

Despite JCPyV being a significant human pathogen, many questions about its etiology remain unresolved. The species specificity of JCPyV is highly restricted to humans, an obstacle that has stymied efforts to develop an animal model to follow the path of the virus from initial infection to CNS penetration.

The current study focused on identifying determinants of tissue tropism of JCPyV in two known sites of JCPyV infection, the brain and the kidney, using labeled virus, and identified

receptors as markers to trace JCPyV interaction with specific cell types in the human host. This work has relevance in understanding the basic mechanism by which JCPyV engages its target cell(s) in the host and its route to the CNS, as well as clinical interest in that it suggests possibilities for specific interference of infection.

Materials and Methods

Virus Purification and Labeling

Generation of the JCPyV virus strain Mad-1/SVE Δ has been described previously.^{40,41} Purified JCPyV was labeled with Alexa Fluor 488 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Labeled virus was added to kidney sections at concentrations of 2 and 20 μ g/mL on brain sections.

Tissue Preparation and IHC Staining

Human brain (from frontal and parietal lobe), choroid plexus, meningeal, and kidney tissues (Table 1) were obtained from the National NeuroAIDS Tissue Consortium⁴² and from Rhode Island Hospital (Providence, RI) in accordance with protocols approved by the Institutional Review Boards at Brown University (Providence, RI) and Rhode Island Hospital. Neural tissues selected as normal controls were from patients who were HIV-seronegative and died of causes not related to HIV/AIDS. Formalin-fixed, paraffin-embedded slides were deparaffinized in xylene followed by a series of graded ethanol washes and subjected to sodium citrate antigen retrieval if necessary. Fresh-frozen brain tissues were embedded in OCT, sectioned, and fixed for 10 minutes in 70% acetone and 30% ethanol at 4°C before staining. Sections were stained with antibodies against mucin (MUC)-1 (sc-53377; Santa Cruz Biotechnology, Dallas, TX), 5-HT_{2A} [S1001-16 (US Biological, Salem, MA) and LS-A1106 (LSBio, Seattle, WA)], 5-HT_{2B} [S-1001-17A (US Biological) and HPA012867 (Sigma, St. Louis, MO)], 5-HT_{2C} [AB9507 (Millipore, Billerica, MA) and LS-A1119 (LSBio)], T antigen (Ab-2; Millipore), JCPyV VP1 (pAb 597⁴³; gifted by Dr. Edward Harlow, Harvard Medical School, Boston, MA), carbonic anhydrase II⁴⁴ (PC076; The Binding Site, Birmingham, UK), glial fibrillary acidic protein (G-A-5; Sigma), OLIG2 (MABN50; Millipore), and CD68 (Cell Marque, Rocklin, CA). For immunofluorescence detection, slides were then incubated in secondary antibody conjugated to Alexa Fluor 488 or 594 at 10 μ g/mL (Invitrogen) and mounted in media containing DAPI (Vector Laboratories, Burlingame, CA). For lectin staining, slides were blocked with carbohydrate-free blocking solution and streptavidin/biotin block (Vector Laboratories) and incubated with biotinylated *Polyporus squamosus* lectin (PSL) at 20 μ g/mL (E-Y Laboratories, San Mateo, CA), followed by streptavidin conjugated to Alexa Fluor 488 or 594 at 3.3 μ g/mL (Vector Laboratories). For immunohistochemistry, primary antibody incubation slides were stained with ImmPRESS Universal secondary antibody (Vector Laboratories) and developed using the DAB system

Table 1 Human Patient Information

Subject	Tissue type	Age	Sex	Race	HIV	PML	Pathology	Cause of death
1	Brain	36	M	W	+	+	PML	HIV/AIDS
2	Brain	30	M	W	+	+	PML	HIV/AIDS
3	Brain	51	M	W	+	+	PML	HIV/AIDS
4	Brain	47	M	W	+	+	PML	HIV/AIDS
5	Brain	46	M	NR	+	+	PML	HIV/AIDS
6	Brain	39	F	NR	+	+	PML	HIV/AIDS
7	Brain	43	M	NR	+	+	PML	HIV/AIDS
8	Brain	45	M	NR	+	+	PML	HIV/AIDS
9	Brain	84	M	NR	—	+	PML	PML
10	Brain	64	F	W	—	+	PML	PML
11	Brain	44	M	W	+	—	HIV no E	HIV/AIDS
12	Brain	46	M	W	+	—	HIV no E	HIV/AIDS
13	Brain	48	M	W	+	—	HIV no E	HIV/AIDS
14	Brain	69	F	W	—	—	Normal	Myocardial infarction
15	Brain	57	M	W	—	—	Normal	Myocardial infarction
16	Brain	59	M	W	—	—	Normal	Cardiac arrhythmia
17	Kidney	50	M	W	—	—	Normal	NA
18	Kidney	67	F	W	—	—	Normal	NA
19	Kidney	41	F	W	—	—	Normal	NA
20	Kidney	32	M	W	—	—	Normal	NA

F, female; M, male; HIV no E, HIV-positive patient with no observed encephalopathy; NA, not applicable; NR, not recorded; PML, progressive multifocal leukoencephalopathy; W, white.

(Vector Laboratories) according to the manufacturer’s protocol. Slides were then counterstained with hematoxylin. To determine areas of demyelination, PML tissue sections were deparaffinized as described in *Tissue Preparation and IHC Staining*, then incubated in Luxol fast blue solution (Sigma)

for 2 hours at 60°C. Slides were decolorized in ethanol and then differentiated in saturated lithium carbonate. The samples were then counterstained with hematoxylin and eosin. Tissues were analyzed using an Eclipse E800 microscope (Nikon, Melville, NY) equipped with an ORCA-ER digital camera (Hamamatsu

Figure 1 Attachment of the human polyomavirus (JCPyV) to kidney tubules is mediated by lactoseries tetrasaccharide c (LSTc). **A:** Immunofluorescence detection shows that JCPyV-488 (green; DAPI stained nuclei, blue) binds to the apical side of kidney tubules. **B:** Removal of sialic acid binding sites with neuraminidase abolishes JCPyV binding. **C** and **D:** LSTc pretreatment inhibits JCPyV binding (**C**), whereas in a serial section (**D**) LSTb pretreatment has no effect on JCPyV attachment to tubules. **E:** Colocalization analysis with the marker MUC-1 (red) demonstrates that JCPyV-488 (green) specifically binds to distal tubules and collecting ducts of the kidney. **F:** *Polyporus squamosus* lectin (PSL), a lectin recognizing the terminal trisaccharide of LSTc, labels distal tubules and collecting ducts (PSL, green; MUC1, red). **G:** PSL label is removed with neuraminidase. **H:** JCPyV (green) colocalizes with the lectin PSL (red). Scale bars: 25 μm.

Figure 2 Viral entry receptor expression and human polyomavirus (JCPyV) binding to kidney distal tubules. Double immunofluorescence analysis demonstrates that virus entry receptors serotonin (5-HT) 2A (A), 5-HT_{2B} (C), and 5-HT_{2C} (E) (red) colocalize with distal tubule and collecting duct marker MUC-1 (green). B, D, and F show that labeled JCPyV (green) colocalizes with each of the 5-HT₂ receptor family members: 5-HT_{2A} (B), 5-HT_{2B} (D), and 5-HT_{2C} (F) (red). Scale bars: 25 μ m.

Photonics KK, Hamamatsu, Japan) and OpenLAB software version 5.5.1 (Agilent Technologies, Santa Clara, CA).

Neuraminidase Treatment

Slides were rehydrated and then incubated in Neuraminidase Type V from *Clostridia perfringens* (Sigma) at 1 U/mL in phosphate-buffered saline supplemented with 1 mmol/L CaCl₂ and 1 mmol/L MgCl₂ (pH 6.0) for 1 hour at 37°C before blocking and incubation with lectin or virus.

LSTb/LSTc Competition

JCPyV-488 was preincubated with either 10 mmol/L of LSTb or LSTc (V labs, Covington, LA) in phosphate-buffered saline for 2 hours on ice, with mixing every 15 minutes (1 μ g/mL final virus concentration). The JCPyV–LST complexes were then added to tissue sections that had been rehydrated and blocked as described in *Tissue Preparation and IHC Staining* and incubated overnight at

4°C. Slides were then washed in FTA hemagglutination buffer (Becton Dickinson, Franklin Lakes, NJ) and analyzed for virus binding by immunofluorescence.

Results

JCPyV Specifically Binds to the Distal Tubules and Collecting Ducts of the Normal Human Kidney via Interaction with LSTc

Incubation of kidney tissues with fluorescently labeled JCPyV demonstrated virus attachment to the apical side of tubules (Figure 1A). This binding was mediated by sialic acid, as pretreatment of the tissue with neuraminidase inhibited binding by removing the sialic acid terminal sugars from the cell surface (Figure 1B). It is known that JCPyV specifically binds to the sialic acid pentasaccharide LSTc.³⁷ To test whether the binding is specific for LSTc, the virus was preincubated with LSTc before addition to tissue samples. This pretreatment also inhibited virus binding (Figure 1C). If however the virus was preincubated with LSTb, no inhibition of virus attachment was observed (Figure 1D). LSTb is identical to LSTc in molecular weight and composition but features a branching rather than linear α 2,6-linked sialic acid. Therefore, JCPyV binding to the kidney tissue is likely mediated by sialic acid interactions, specifically with LSTc. The preferential binding sites of JCPyV in the kidney were distal tubules and collecting ducts, as shown by colocalization of the virus with the marker MUC1 (Figure 1E).^{45,46} JCPyV binding was observed in these tubules in both the medulla and cortex of the kidney. Although some MUC1⁺ tubules did not appear to be bound by JCPyV, we did not observe JCPyV⁺ tubules that were MUC1[−]. On extended incubation times and high virus concentration, a small amount of virus binding to Bowman's capsule, to endothelial cells of the glomeruli, and to proximal tubules could be observed, but this binding was minor compared with that to the collecting ducts and distal tubules.

The nature of JCPyV binding to the kidney was further analyzed using PSL, a lectin from the mushroom *Polyporus squamosus*. PSL has high specificity toward nonreducing terminal Neu5Ac α 2,6Gal β 1,4GlcNAc, the terminal trisaccharide sequence of LSTc^{47,48} of asparagine-linked (N-linked) oligosaccharides. PSL is more specific than is the more commonly used *Sambucus nigra* lectin, which also detects terminal α 2,6-linked N-acetylneuraminic acid present on serine/threonine-linked oligosaccharides.⁴⁹ In the kidney, PSL exhibits a binding profile broader than that of JCPyV, binding to the distal tubules and collecting ducts, glomeruli, and endothelium. JCPyV bound mostly to the apical side of the tubules, whereas PSL labeled the basal and lateral sides of these cells as well. Neuraminidase treatment removed lectin binding sites (Figure 1G). This finding demonstrated that an α 2,6 sugar closely related to LSTc was on the kidney structures to which JCPyV bound, especially

Figure 3 Human polyomavirus (JCPyV) receptor expression and virus binding in the choroid plexus. **A:** JCPyV-488 (green) binding to choroid plexus epithelium. **B:** *Polyporus squamosus* lectin (PSL; red) binding to choroid plexus. **C:** JCPyV-488 (green) and PSL (red) colocalize to blood vessels in the choroid plexus. Serotonin (5-HT) 2A (**D**), 5-HT_{2B} (**E**), and 5-HT_{2C} (red) (**F**) are expressed in choroid plexus epithelium. **G:** Treatment of choroid plexus with neuraminidase removes JCPyV binding sites. **H:** PSL binding is abolished following neuraminidase treatment. **I:** Secondary antibody only. Scale bars: 25 μ m.

the distal tubules and collecting ducts (Figure 1, F and G). JCPyV and PSL colocalized on the same kidney distal tubules and collecting ducts. There were occasionally PSL⁺ tubules that were JCPyV⁻ but not PSL⁻ tubules that were JCPyV⁺ (Figure 1H).

In addition to the sialic acid motif necessary for specific JCPyV attachment to cells, the 5-HT₂ family of 5-HT receptors were also expressed on the distal tubules and collecting ducts of the normal human kidney (Figure 2). It is known that the 5-HT₂ family of receptors is the functional receptor for JCPyV entry into cells.^{38,39,50} All three 5-HT₂ family members colocalized with MUC1 on the collecting ducts and distal tubules of the kidney (Figure 2, A, C, and E). 5-HT_{2A} appears specifically on the apical side of the tubules, whereas 5-HT_{2B} and 5-HT_{2C} also label the basolateral sides. Fluorescently labeled JCPyV also colocalized in the kidney with 5-HT_{2A}, 5-HT_{2B}, and 5-HT_{2C} (Figure 2, B, D, and F).

JCPyV Specifically Binds to Choroid Plexus Epithelium and Meninges

Similar to those of the distal tubules of the kidney, the cells of the choroid plexus epithelium (CPE) and the meninges expressed both the attachment and entry receptors for JCPyV. Labeled JCPyV bound to the apical and basolateral sides of the CPE (Figure 3A), and this attachment was dependent on the presence of sialic acid as neuraminidase treatment removed virus binding sites (Figure 3G). PSL also bound to CPE (Figure 3B), and the binding was sialic acid-dependent as it was abolished by neuraminidase (Figure 3H). The CPE also expressed all three of the 5-HT₂ receptors (Figure 3, D–F and I). In addition to the CPE, JCPyV bound to the blood vessels in the choroid plexus and colocalized with PSL binding (Figure 3C). In the meninges, JCPyV bound to sialic acid receptors on meningeal cells (Figure 4, A, E, and G). Meningeal cells also expressed the

Figure 4 Human polyomavirus (JCPyV) receptor expression and virus binding in the meninges. Colocalization of JCPyV with *Polyporus squamosus* lectin (PSL) (A), serotonin (5-HT) 2A (B), 5-HT_{2B} (C), and 5-HT_{2C} (D). E: JCPyV-488 (green) and PSL (red) colocalize to blood vessels in the meninges. F: A CD68⁺ cell (red) in the stroma of the meninges is bound by JCPyV-488 (green). G: Neuraminidase treatment removes JCPyV binding sites. H: Secondary antibody only. Scale bars: 25 μm (A–E, G and H); 10 μm (F).

three members of the 5-HT₂ subtypes (Figure 4, B–D and H). The virus bound to the meningeal vessels (Figure 4E) as well as to CD68⁺ cells in the stroma (Figure 4F).

JCPyV Specifically Binds to LSTc⁺ Microglial Cells and Brain Vascular Endothelial Cells But Not to Oligodendrocytes or Astrocytes that Are LSTc[–] But 5-HT Receptor⁺

In contrast to the kidney and choroid plexus, JCPyV attachment and entry receptors were expressed on different glial cells in human brain parenchyma, as summarized in Table 2. Oligodendrocytes expressed 5-HT_{2B} and 5-HT_{2C} and were LSTc[–] (Figure 5, A, D, G, and J). Astrocytes expressed 5-HT_{2A} and 5-HT_{2B} but were 5-HT_{2C} and LSTc[–] (Figure 5, B, E, H, and K). Microglia, on the other hand, did not appear to express any of the 5-HT₂ family members but had abundant LSTc-like sugar on their surfaces (Figure 5, C, F, I and L and Figure 6A). JCPyV bound only to the LSTc⁺ microglial cells and brain endothelial cells (Figure 6A),

consistent with the observation that LSTc is the primary attachment receptor for the virus. Treatment of the brain tissue with neuraminidase eliminated virus binding (Figure 6B). These interactions were specific for LSTc, as virus binding was unaffected by preincubation with LSTb, but virus binding was abolished by competition with LSTc (Figure 6, C and D). PSL labeling of microglia and neuroendothelium was also removed by neuraminidase (Figure 6, E and F). Virus attachment and receptor expression patterns were the same in both formalin-fixed, paraffin-embedded and fresh-frozen brain tissues (Supplemental Figure S1).

JCPyV Attachment and Entry Receptor Expression in PML Brain

Sections of brain parenchyma from patients with PML were treated with Luxol fast blue staining for the visualization of demyelinated lesions. The sections were also analyzed for virus binding to cells in the lesions as well as virus attachment and entry receptors expressed by specific cell types,

Table 2 Summary of Receptor Expression and JCPyV Attachment in Brain Parenchyma

Receptor	Oligodendrocyte	Astrocyte	Neuron	Microglia	Neuroendothelium
5-HT _{2A}	–	+	+	–	–
5-HT _{2B}	+	+	+	–	–
5-HT _{2C}	+	–	+	–	–
PSL	–	–	–	+	+
JCPyV	–	–	–	+	+

JCPyV, human polyomavirus; PSL, *Polyporus squamosus* lectin.

Figure 5 Glial cell type—specific expression of human polyomavirus (JCPyV) attachment and entry receptors in the brain. JCPyV entry receptors serotonin (5-HT) 2A, 2B, and 2C, and attachment receptor marker *Polyporus squamosus* lectin (PSL) (green) colabel with glial cell type markers carbonic anhydrase II (oligodendrocyte) (A, D, G, and J), glial fibrillary acidic protein (astrocyte) (B, E, H, and K), and CD68 (microglia) (C, F, I, and L) (red). Scale bars: 25 μ m.

using immunohistochemistry analysis. The lesions were readily discernable (Figure 7, A and G), and the expression of LSTc as determined by PSL binding was restricted to microglia and monocyte or macrophage cells infiltrating the lesions (Figure 7, B–D). Virus bound only to LSTc⁺ microglial cells and infiltrating monocytes or macrophages and did not bind to the LSTc[−] oligodendrocytes or astrocytes (Figure 7, E and F). This finding is consistent with the role that LSTc plays in attachment but it is inconsistent with the fact that virus targets oligodendrocytes and astrocytes, but not microglia, for infection. LSTc was not detected on either oligodendrocytes or astrocytes, but these cells did express 5-HT₂ receptors (Figure 7, H–K), similar to findings observed in normal brain. Oligodendrocytes were positive for expression of the late viral protein 1 (VP1), indicating that these cells were lytically infected by JCPyV (Figure 7L).

Although we did not observe 5-HT_{2A}—expressing VP1⁺ cells (Figure 7M), JCPyV-infected glial cells expressing 5-HT_{2B} and 5-HT_{2C} were present in the PML lesions (Figure 7, N and O).

Discussion

In vitro experiments have shown that for productive host cell infection, JCPyV requires surface expression of the attachment receptor LSTc as well as one of the members of the 5-HT₂ family, G protein—coupled receptors required for entry.^{37,38} In the present study, we investigated the *in vivo* expression of these receptors in human kidney and brain, the main sites of latency/persistence and pathogenesis, respectively, and compared receptor-expression profiles with the pattern of virus attachment. Here, we show that virus

Figure 6 Human polyomavirus (JCPyV) binds to brain endothelium and microglial cells via attachment receptor lactoseries tetrasaccharide c (LSTc). **A:** Colocalization with CD68 (red) shows that JCPyV-488 binds to microglial cells. **Arrow** indicates neuroendothelium. **B:** Treatment with neuraminidase abolishes virus binding. **C:** Competition with LSTb does not affect JCPyV-488 binding to brain. **D:** Competition with LSTc abolishes JCPyV-488 binding to brain tissue. **E:** *Polyporus squamosus* lectin (PSL; red) labels microglia and neuroendothelium. **F:** PSL no longer binds to brain tissue following treatment with neuraminidase. Scale bars: 25 μ m.

binding to the plasma membrane depends on the presence of LSTc.

In addition, the attachment and entry receptors were coexpressed in the kidney tubule epithelium and CPE, two cell types that the virus has been shown to infect, whereas in the brain parenchyma, the entry receptors were present on the main targets of JCPyV infection, and the attachment receptors were instead largely expressed on neuroendothelium and cells of myeloid lineage, suggesting potential mechanisms of entry into the CNS. We did not observe qualitative differences in the binding of antibodies, lectins, or virus to tissues from different patients.

JCPyV Attachment to Renal Tubules

JCPyV binds specifically to the distal tubule epithelium and collecting ducts in the human kidney. JCPyV infection has

previously been shown in the tubular epithelium of immune-suppressed patients. By *in situ* hybridization, JCPyV DNA was detected in the collecting tubules of a PML patient.⁵¹ JCPyV VP1 protein has been detected in the epithelial tubules in kidneys of AIDS patients⁵² and renal transplant recipients,^{53–55} and one report of a non-PML renal cancer patient described JCPyV in collecting ducts.⁵⁶ Although not nearly as often as the closely related polyomavirus BKPyV, JCPyV can cause JCPyV-associated nephropathy.^{57,58} Here, we show that virus binding is dependent on the virus attachment receptor, as shown by specific LSTc competition assay. The lectin used for detecting LSTc-like sugars not only bound predominantly to distal tubules and collecting ducts but also detected α 2,6 sialic acid on kidney endothelium, glomeruli, and Bowman's capsule. However, only minor virus attachment to these nontubular cells was observed after prolonged virus exposure. It is possible that either the lectin is detecting a sugar other than LSTc or that an additional factor is contributing to additional specificity of virus attachment to the distal tubules and collecting ducts. JCPyV entry into cells depends on the presence of 5-HT₂ receptors, and the distal tubules and collecting ducts express each of these receptors, suggesting that the virus can attach and enter these cells to cause persistent infection and, in some cases, pathogenesis.

Direct Binding of JCPyV to Barriers of the CNS

To infect cells in the brain and cause neurological disease, JCPyV must cross one of the barriers that protect neural tissue from the periphery, the blood–brain barrier (BBB) and the blood–cerebrospinal fluid barrier (BCSFB), which restrict the passage of cells and microbes between the peripheral circulation, brain, and CSF. How JCPyV crosses these obstacles to the CNS is not yet known. Here, we demonstrate that JCPyV attaches via LSTc directly to neuroendothelial cells that make up part of the BBB. Although the virus binds avidly to the neuroendothelium, these cells are not considered target host cells for JCPyV, and we did not detect entry receptor expression in brain microvascular cells. In rare cases, *in situ* hybridization experiments have detected JCPyV DNA in brain endothelium of PML patients,^{59,60} and JCPyV infection of cultured human brain microvasculature endothelial cells has been reported *in vitro*,⁶¹ but productive JCPyV infection has not been shown in neuroendothelium of human tissue.

The BBB forms an interface between the bloodstream and the CNS and is composed of highly specialized endothelial cells bound by tight junctions, astrocytic endfeet, the capillary basement membrane, and pericytes embedded in this extracellular matrix. The migration of cells from the periphery to the brain parenchyma is highly regulated, and under normal conditions the BBB blocks circulating monocytes from migrating into the brain. However, these structures must be dynamically regulated to allow a small population of lymphocytes engaged in immune surveillance to pass into the brain parenchyma.^{62,63}

Figure 7 Human polyomavirus (JCPyV) binding, receptor expression, and infection in demyelinating lesions of progressive multifocal leukoencephalopathy (PML). **A, B, and G–K:** Serial sections of a PML brain were used for immunohistochemistry staining. **A:** PML brain stained with Luxol fast blue (Sigma) and hematoxylin and eosin (H&E). **B:** Serial section of **A** stained with *Polyporus squamosus* lectin (PSL). **C–F and L–O:** Immunofluorescence staining images of a PML lesion. **C:** Cells in lesion labeled with PSL (red). **D:** The PSL⁺ cells are CD68⁺ (green). **E:** Cells in lesion labeled with JCPyV-488. **F:** Cells in lesion colabeled with JCPyV-488 and CD68. **G:** PML brain stained with Luxol fast blue and H&E. **H:** Serial section of same lesion labeled with serotonin (5-HT) 2A. **I:** Higher magnification of boxed region in **H**, 5-HT_{2A} in PML lesion. **J:** Cells in PML lesion labeled with 5-HT_{2B}. **K:** Cells in PML lesion labeled with 5-HT_{2C}. JCPyV-infected cells of a PML lesion express virus entry receptors. **L–O:** Cells in lesion labeled with viral protein (VP)-1 (red) and oligodendrocyte marker carbonic anhydrase II (green) (**L**), VP1 (red) and 5-HT_{2A} (green) (**M**), VP1 (red) and 5-HT_{2B} (green) (**N**), and VP1 (red) and 5-HT_{2C} (green) (**O**). Scale bars: 50 μm (**A, B, G, and H**); 25 μm (**C–F**); 10 μm (**I–K**); 5 μm (**L–O**).

and also circulating monocytes to replace perivascular macrophages.^{64,65} Some pathological conditions such as viral or bacterial infection can disrupt the integrity of the BBB and allow less restricted passage of leukocytes from the systemic circulation into the brain and additional monocytes to enter the brain.^{66,67} During the course of HIV infection, monocytes cross in response to proinflammatory cytokines released by astrocytes and parenchymal myeloid cells.^{68,69} After HIV neuroinvasion, the BBB is disrupted as a result of loss of transmembrane tight junction integrity in the neuroendothelium,⁷⁰ and glycoprotein 120 has been shown to contribute to BBB leakiness, perhaps by increased expression of proteases.⁷¹ Also, elevated levels of lipopolysaccharide as a result of bacterial infection can

compromise the BBB.^{72,73} Lipopolysaccharide can also increase endocytic activity of brain microendothelial cells.⁷⁴ It is possible that JCPyV already bound to the neuroendothelium enters the brain parenchyma after transient disruption of the BBB.

The BCSFB, or choroid plexus, constitutes another potential site of JCPyV entry into the CNS. The BCSFB is formed by a monolayer of polarized epithelial cells enclosing a highly vascularized stroma populated with a variety of cell types, including fibroblasts and macrophages.⁷⁵ Like the endothelial cells of the BBB, the CPE cells express tight junctions and serve as a barrier to separate the CNS from the circulation, and the migration across the BCSFB is restricted.

However, monocytes^{76,77} and T cells⁷⁸ have been shown to enter the CNS via the BCSFB in response to injury. It is known that JCPyV entry 5-HT₂ receptors are expressed in the CPE^{79,80} and that 5-HT_{2C} isolated from the rat choroid plexus is N-glycosylated.⁸¹ Gene-profiling studies in the rat choroid plexus have shown that chronic stress affects the levels of expression of serotonin 5-HT₂ family expression.⁸² Here, we show that the CPE expresses both the JCPyV attachment and entry receptors and that the virus interaction with the CPE is LSTc dependent. Recently, JCPyV VP1 was detected in the CPE in a case of JCPyV-associated meningitis,⁸³ demonstrating that JCPyV can productively infect these cells. Direct infection of the CPE could allow JCPyV access to brain parenchyma.

Profile of Virus Attachment in the Brain

In the brain parenchyma, JCPyV binds specifically to microglial cells, the resident immune cells of the CNS. This interaction is mediated by the virus attachment receptor LSTc as virus binding is blocked by competition with LSTc and when the tissue is treated with neuraminidase. Although the microglia can support virus attachment, these cells are not known to be infected by JCPyV. Microglia are long-lived tissue macrophages unique to the neural tissue. Under normal conditions, the microglia extend and retract their thin, highly ramified cell processes to continuously monitor the immediate microenvironment.⁸⁴ The processes of each microglial cell do not overlap; each cell surveys its own territory⁸⁵; and some cells, the juxtavascular microglia, directly contact the basal lamina of blood vessels.⁸⁶ On injury to the brain, including infection, inflammation, and trauma, microglial cells undergo a transformation from a resting to an activated state, assuming an ameboid shape and migrating to the site of injury to phagocytose dead cells, clear extracellular debris, and produce cytokines.^{87–89} On damage to the CNS (including in PML lesions), circulating immune cells, including peripherally derived monocytes, macrophages, and dendritic cells, are recruited to the brain parenchyma. Additional myeloid cells in the CNS are found at the junctions where the brain parenchyma meets the rest of the CNS, including perivascular cells, and macrophages and monocyte-derived cells resident in the choroid plexus and meninges.⁹⁰ These cells have distinct embryological origins but share many markers and membrane properties and similar functions, including local immune surveillance and debris removal.

JCPyV is not known to infect microglia. However, recent reports have shown polyomaviruses interact with CD68⁺ cells in other organs. Human polyomavirus KI infects CD68⁺ cells in the human lung,⁹¹ and one study demonstrated that JCPyV and BKPyV viruslike particles are taken up by mouse CD68⁺ cells in the mouse liver when administered i.v.⁹² Here we show that JCPyV attaches to the plasma membranes of CD68⁺ monocyte/macrophages in the stroma of the choroid plexus and meninges. It is possible

that the virus enters the brain bound to the outside of an LSTc⁺ cell and then infects oligodendrocytes and astrocytes through a mechanism not yet defined.

JCPyV is known to infect oligodendrocytes, astrocytes, and neurons. JCPyV infection of oligodendrocytes leads to cell destruction and subsequent demyelinating lesions and loss of neuronal function. Astrocytes have also been shown to support JCPyV replication in the PML brain, and infection of neurons has been described in JCPyV neuropathy and encephalopathy. Here we show that the cell types that are known to be infected by JCPyV express entry receptors that would allow virus entry to permit a productive infection. However, we did not observe the presence of an attachment receptor on these cells, nor did we observe appreciable JCPyV binding to the plasma membrane of these cells. It should be noted that productive viral replication is not solely dependent on the presence of the 5-HT₂ receptors, as many cell types that express 5-HT₂ receptors are not infected by JCPyV. Multiple cellular factors, some known and some yet to be discovered, dictate the ability of the virus to productively infect a host cell. Elucidating the factors necessary for permitting productive infection in a host cell is an important component of understanding viral pathogenesis. In our study we observed entry receptor expression in astrocytes, particularly in the reactive astrocytes in the PML brain. It is possible that the virus enters these cells by a mechanism that does not require attachment receptors on the host cell plasma membrane. This concept may explain the evolution of mutants in PML brain that have lost the ability to bind sialic acid.^{93–95}

Conclusion

JCPyV infects approximately half of the population worldwide.^{1,2} After initial infection, the virus persists in the kidney, tonsils, bone marrow, and most likely the brain. After reactivation, the virus can be shed in the urine and usually does not cause disease. However, under conditions of immune suppression, such as HIV/AIDS or treatment with immunomodulatory therapies, JCPyV levels increase and in some patients pathology is observed, either in the brain or, in rare cases, the kidney. It appears that the loss of T cells and their immune surveillance is necessary for the progression of JCPyV pathogenesis. The mechanisms by which JCPyV enters the CNS remain unknown. Here we demonstrate that virus binds specifically to the neuroendothelial cells of the BBB. It is possible that on disruption of the BBB, either transient, in normal brain, or under conditions of pathogenesis, the virus migrates into the brain parenchyma. JCPyV also binds to the plasma membranes of monocytes that infiltrate the brain on BBB disruption, providing an additional mechanism for JCPyV to reach the parenchyma. An alternative pathway to the CNS is via JCPyV infection of the choroid plexus. Once JCPyV is in the brain, glial cells are exposed and infected by JCPyV by an as-yet undefined

mechanism. With the increase in immune-suppressing therapies used for addressing autoimmune conditions, more patients are potentially at risk for PML. The identification of the pathways from the environment to the CNS and of agents to block viral infection is essential for developing antiviral therapies for this incurable disease.

Acknowledgments

We thank the members of the Atwood Laboratory for critical discussion and review of the manuscript and Leila Noble (RIH Molecular Pathology Core) and Nancy Heath (Division of Neuropathology) for technical assistance. pAb 597 antibody was gifted by Dr. Edward Harlow (Harvard Medical School, Boston, MA).

Supplemental Data

Supplemental material for this article can be found at <http://dx.doi.org/10.1016/j.ajpath.2015.04.003>.

References

- Kean JM, Rao S, Wang M, Garcea RL: Seroepidemiology of human polyomaviruses. *PLoS Pathog* 2009, 5:e1000363
- Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, Miller E: Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. *J Med Virol* 2003, 71:115–123
- Dorries K: Molecular biology and pathogenesis of human polyomavirus infections. *Dev Biol Stand* 1998, 94:71–79
- Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH: Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. *J Infect Dis* 2009, 199:837–846
- Monaco MC, Jensen PN, Hou J, Durham LC, Major EO: Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. *J Virol* 1998, 72:9918–9923
- Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO: JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. *J Virol* 1996, 70:7004–7012
- Grinnell B, Padgett B, Walker D: Distribution of nonintegrated DNA from JC papovavirus in organs of patients with progressive multifocal leukoencephalopathy. *J Infect Dis* 1983, 147:669–675
- Newman JT, Frisque RJ: Detection of archetype and rearranged variants of JC virus in multiple tissues from a pediatric PML patient. *J Med Virol* 1997, 52:243–252
- Atwood WJ, Amemiya K, Traub R, Harms J, Major EO: Interaction of the human polyomavirus, JCV, with human B-lymphocytes. *Virology* 1992, 190:716–723
- Major EO, Amemiya K, Elder G, Houff SA: Glial cells of the human developing brain and B cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus, JCV. *J Neurosci Res* 1990, 27:461–471
- Caldarelli-Stefano R, Vago L, Omodeo-Zorini E, Mediati M, Losciale L, Nebuloni M, Costanzi G, Ferrante P: Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. *J Neurovirol* 1999, 5:125–133
- Bayliss J, Karasoulos T, McLean CA: Immunosuppression increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy. *J Infect Dis* 2013, 207:133–136
- Tan CS, Ellis LC, Wuthrich C, Ngo L, Broge TA Jr, Saint-Aubyn J, Miller JS, Koralnik IJ: JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. *J Virol* 2010, 84:9200–9209
- Gheuens S, Wuthrich C, Koralnik IJ: Progressive multifocal leukoencephalopathy: why gray and white matter. *Annu Rev Pathol* 2013, 8:189–215
- Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A: PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. *Neurology* 2013, 80:1430–1438
- Astrom K, Mancall E, Richardson EP Jr: Progressive multifocal leukoencephalopathy. *Brain* 1958, 81:93–127
- Brooks B, Walker D: Progressive multifocal leukoencephalopathy. *Neurol Clin* 1984, 2:299–313
- Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW: Progressive multifocal leukoencephalopathy in HIV-1 infection. *Lancet Infect Dis* 2009, 9:625–636
- Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO: Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. *Clin Microbiol Rev* 2012, 25:471–506
- Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, Mahamat A, Rabaud C, Costagliola D: Clinical Epidemiology Group of the French Hospital Database on HIV: Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. *HIV Med* 2008, 9:246–256
- Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL: Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. *Lancet Oncol* 2009, 10:816–824
- Major EO: Reemergence of PML in natalizumab-treated patients—new cases, same concerns. *N Engl J Med* 2009, 361:1041–1043
- Van Assche G, Van Ranst M, Sciort R, Dubois B, Vermeire S, Noman M, Verbeeck J, Geboes K, Robberecht W, Rutgeerts P: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. *N Engl J Med* 2005, 353:362–368
- Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. *N Engl J Med* 2005, 353:369–374
- Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. *N Engl J Med* 2005, 353:375–381
- Zaheer F, Berger JR: Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. *Ther Adv Drug Saf* 2012, 3:227–239
- Koralnik IJ, Wuthrich C, Dang X, Rottnek M, Gurtman A, Simpson D, Morgello S: JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. *Ann Neurol* 2005, 57:576–580
- Wuthrich C, Dang X, Westmoreland S, McKay J, Maheshwari A, Anderson MP, Ropper AH, Viscidi RP, Koralnik IJ: Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. *Ann Neurol* 2009, 65:742–748
- Randhawa P, Baksh F, Aoki N, Tschirhart D, Finkelstein S: JC virus infection in allograft kidneys: analysis by polymerase chain reaction and immunohistochemistry. *Transplantation* 2001, 71:1300–1303
- Lautenschlager I, Jahnukainen T, Kardas P, Lohi J, Auvinen E, Mannonen L, Dumoulin A, Hirsch HH, Jalanko H: A Case of Primary

- JC Polyomavirus Infection-Associated Nephropathy. *Am J Transplant* 2014, 14:2887–2892
31. Drachenberg CB, Hirsch HH, Papadimitriou JC, Gosert R, Wali RK, Munivenkatappa R, Nogueira J, Cangro CB, Haririan A, Mendley S, Ramos E: Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. *Transplantation* 2007, 84:323–330
 32. Kazory A, Ducloux D, Chalopin JM, Angonin R, Fontaniere B, Moret H: The first case of JC virus allograft nephropathy. *Transplantation* 2003, 76:1653–1655
 33. Shah KV: Polyomaviruses. *Fields Virology*, 3rd Edition. Edited by Fields BN, Knipe DM, Howley PM. Philadelphia, PA, Lippincott-Raven, 1996. pp. 2027–2043
 34. Dugan AS, Gasparovic ML, Atwood WJ: Direct correlation between sialic acid binding and infection of cells by two human polyomaviruses (JC virus and BK virus). *J Virol* 2008, 82:2560–2564
 35. Komagome R, Sawa H, Suzuki T, Suzuki Y, Tanaka S, Atwood WJ, Nagashima K: Oligosaccharides as receptors for JC virus. *J Virol* 2002, 76:12992–13000
 36. Liu CK, Wei G, Atwood WJ: Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha 2-6 linked sialic acids. *J Virol* 1998, 72:4643–4649
 37. Neu U, Maginnis MS, Palma AS, Stroh LJ, Nelson CD, Feizi T, Atwood WJ, Stehle T: Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. *Cell Host Microbe* 2010, 8:309–319
 38. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ: The human polyomavirus, JCV, uses serotonin receptors to infect cells. *Science* 2004, 306:1380–1383
 39. Assetta B, Maginnis MS, Gracia Ahufinger I, Haley SA, Gee GV, Nelson CD, O'Hara BA, Allen Ramdial SA, Atwood WJ: 5-HT2 receptors facilitate JC polyomavirus entry. *J Virol* 2013, 87:13490–13498
 40. Liu CK, Atwood WJ: Propagation and assay of the JC virus. *Methods Mol Biol* 2001, 165:9–17
 41. Nelson CD, Carney DW, Derdowski A, Lipovsky A, Gee GV, O'Hara B, Williard P, DiMaio D, Sello JK, Atwood WJ: A retrograde trafficking inhibitor of ricin and Shiga-like toxins inhibits infection of cells by human and monkey polyomaviruses. *MBio* 2013, 4. e00729-13
 42. Morgello S, Gelman BB, Kozlowski PB, Vinters HV, Masliah E, Cornford M, Cavert W, Marra C, Grant I, Singer EJ: The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease. *Neuropathol Appl Neurobiol* 2001, 27:326–335
 43. Atwood WJ, Wang L, Durham LC, Amemiya K, Traub RG, Major EO: Evaluation of the role of cytokine activation in the multiplication of JC virus (JCV) in human fetal glial cells. *J Neurovirol* 1995, 1:40–49
 44. Henmi C, Sawa H, Iwata H, Orba Y, Tanaka S, Nagashima K: Establishment of an immunoscreening system using recombinant VP1 protein for the isolation of a monoclonal antibody that blocks JC virus infection. *Biochem Biophys Res Commun* 2005, 327:242–251
 45. Howie AJ: Epithelial membrane antigen in normal and proteinuric glomeruli and in damaged proximal tubules. *J Pathol* 1986, 148:55–60
 46. Meehan SM, Kraus MD, Kadambi PV, Chang A: Nephron segment localization of polyoma virus large T antigen in renal allografts. *Hum Pathol* 2006, 37:1400–1406
 47. Mo H, Winter HC, Goldstein IJ: Purification and characterization of a Neu5Acalpha2-6Galbeta1-4Glc/GlcNAc-specific lectin from the fruiting body of the polypore mushroom *Polyporus squamosus*. *J Biol Chem* 2000, 275:10623–10629
 48. Zhang B, Palcic MM, Mo H, Goldstein IJ, Hindsgaul O: Rapid determination of the binding affinity and specificity of the mushroom *Polyporus squamosus* lectin using frontal affinity chromatography coupled to electrospray mass spectrometry. *Glycobiology* 2001, 11:141–147
 49. Toma V, Zuber C, Winter HC, Goldstein IJ, Roth J: Application of a lectin from the mushroom *Polyporus squamosus* for the histochemical detection of the NeuAcalpha2,6Galbeta1,4Glc/GlcNAc sequence of N-linked oligosaccharides: a comparison with the *Samolus nigra* lectin. *Histochem Cell Biol* 2001, 116:183–193
 50. Maginnis MS, Haley SA, Gee GV, Atwood WJ: Role of N-linked glycosylation of the 5-HT2A receptor in JC virus infection. *J Virol* 2010, 84:9677–9684
 51. Dorries K, ter Meulen V: Progressive multifocal leukoencephalopathy: detection of papovavirus JC in kidney tissue. *J Med Virol* 1983, 11:307–317
 52. Boldorini R, Omodeo-Zorini E, Nebuloni M, Benigni E, Vago L, Ferri A, Monga G: Lytic JC virus infection in the kidneys of AIDS subjects. *Mod Pathol* 2003, 16:35–42
 53. Wen MC, Wang CL, Wang M, Cheng CH, Wu MJ, Chen CH, Shu KH, Chang D: Association of JC virus with tubulointerstitial nephritis in a renal allograft recipient. *J Med Virol* 2004, 72:675–678
 54. Kantarci G, Eren Z, Demirag A, Dogan I, Kakalagaoglu F, Yilmaz G: JC virus-associated nephropathy in a renal transplant recipient and comparative analysis of previous cases. *Transpl Infect Dis* 2011, 13:89–92
 55. Delbue S, Ferraresso M, Ghio L, Carloni C, Carluccio S, Belingeri M, Edefonti A, Ferrante P: A review on JC virus infection in kidney transplant recipients. *Clin Dev Immunol* 2013, 2013:926391
 56. Aoki N, Kitamura T, Tominaga T, Fukumori N, Sakamoto Y, Kato K, Mori M: Immunohistochemical detection of JC virus in nontumorous renal tissue of a patient with renal cancer but without progressive multifocal leukoencephalopathy. *J Clin Microbiol* 1999, 37:1165–1167
 57. Hirsch HH, Kardas P, Kranz D, Leboeuf C: The human JC polyomavirus (JCPyV): virological background and clinical implications. *APMIS* 2013, 121:685–727
 58. Nickleleit V, Mihatsch MJ: Polyomavirus nephropathy in native kidneys and renal allografts: an update on an escalating threat. *Transpl Int* 2006, 19:960–973
 59. Dorries K, Johnson RT, ter Meulen V: Detection of polyoma virus DNA in PML-brain tissue by (in situ) hybridization. *J Gen Virol* 1979, 42:49–57
 60. von Einsiedel RW, Samorei IW, Pawlita M, Zwissler B, Deubel M, Vinters HV: New JC virus infection patterns by in situ polymerase chain reaction in brains of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy. *J Neurovirol* 2004, 10:1–11
 61. Chapagain ML, Verma S, Mercier F, Yanagihara R, Nerurkar VR: Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. *Virology* 2007, 364:55–63
 62. Engelhardt B, Ransohoff RM: Capture, crawl, cross: the T cell code to breach the blood-brain barriers. *Trends Immunol* 2012, 33:579–589
 63. Hickey WF: Leukocyte traffic in the central nervous system: the participants and their roles. *Semin Immunol* 1999, 11:125–137
 64. Ivey NS, MacLean AG, Lackner AA: Acquired immunodeficiency syndrome and the blood-brain barrier. *J Neurovirol* 2009, 15:111–122
 65. Annunziata P: Blood-brain barrier changes during invasion of the central nervous system by HIV-1. Old and new insights into the mechanism. *J Neurol* 2003, 250:901–906
 66. Persidsky Y, Ghorpade A, Rasmussen J, Limoges J, Liu XJ, Stins M, Fiala M, Way D, Kim KS, Witte MH, Weinand M, Carhart L, Gendelman HE: Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. *Am J Pathol* 1999, 155:1599–1611
 67. Petit CK, Adkins B, McCarthy M, Roberts B, Khamis I: CD4+ and CD8+ cells accumulate in the brains of acquired immunodeficiency

- syndrome patients with human immunodeficiency virus encephalitis. *J Neurovirol* 2003, 9:36–44
68. Gendelman HE, Ding S, Gong N, Liu J, Ramirez SH, Persidsky Y, Mosley RL, Wang T, Volsky DJ, Xiong H: Monocyte chemotactic protein-1 regulates voltage-gated K⁺ channels and macrophage transmigration. *J Neuroimmune Pharmacol* 2009, 4:47–59
 69. Didier N, Romero IA, Creminon C, Wijkhuisen A, Grassi J, Mabondzo A: Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. *J Neurochem* 2003, 86: 246–254
 70. Maclean AG, Belenchia GE, Bieniemy DN, Moroney-Rasmussen TA, Lackner AA: Simian immunodeficiency virus disrupts extended lengths of the blood–brain barrier. *J Med Primatol* 2005, 34:237–242
 71. Louboutin JP, Reyes BA, Agrawal L, Van Bockstaele EJ, Strayer DS: HIV-1 gp120 upregulates matrix metalloproteinases and their inhibitors in a rat model of HIV encephalopathy. *Eur J Neurosci* 2011, 34:2015–2023
 72. Wispelwey B, Lesse AJ, Hansen EJ, Scheld WM: Haemophilus influenzae lipopolysaccharide-induced blood brain barrier permeability during experimental meningitis in the rat. *J Clin Invest* 1988, 82:1339–1346
 73. Banks WA, Erickson MA: The blood-brain barrier and immune function and dysfunction. *Neurobiol Dis* 2010, 37:26–32
 74. Banks WA, Kastin AJ, Brennan JM, Vallance KL: Adsorptive endocytosis of HIV-1gp120 by blood-brain barrier is enhanced by lipopolysaccharide. *Exp Neurol* 1999, 156:165–171
 75. Johanson C, Stopa E, McMillan P, Roth D, Funk J, Krinke G: The distributional nexus of choroid plexus to cerebrospinal fluid, ependyma and brain: toxicologic/pathologic phenomena, periventricular destabilization, and lesion spread. *Toxicol Pathol* 2011, 39: 186–212
 76. Szmydynger-Chodobska J, Strazielle N, Gandy JR, Keefe TH, Zink BJ, Ghersi-Egea JF, Chodobski A: Posttraumatic invasion of monocytes across the blood-cerebrospinal fluid barrier. *J Cereb Blood Flow Metab* 2012, 32:93–104
 77. Shechter R, London A, Schwartz M: Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. *Nat Rev Immunol* 2013, 13:206–218
 78. Kunis G, Baruch K, Rosenzweig N, Kertser A, Miller O, Berkutzi T, Schwartz M: IFN-gamma-dependent activation of the brain's choroid plexus for CNS immune surveillance and repair. *Brain* 2013, 136: 3427–3440
 79. Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, Nardi I: Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. *Neuroscience* 1999, 92: 601–611
 80. Nichols DE, Nichols CD: Serotonin receptors. *Chem Rev* 2008, 108: 1614–1641
 81. Backstrom JR, Westphal RS, Canton H, Sanders-Bush E: Identification of rat serotonin 5-HT_{2C} receptors as glycoproteins containing N-linked oligosaccharides. *Brain Res Mol Brain Res* 1995, 33: 311–318
 82. Sathyanesan M, Girgenti MJ, Banasr M, Stone K, Bruce C, Guilchick E, Wilczak-Havill K, Nairn A, Williams K, Sass S, Duman JG, Newton SS: A molecular characterization of the choroid plexus and stress-induced gene regulation. *Transl Psychiatry* 2012, 2: e139
 83. Agnihotri SP, Wuthrich C, Dang X, Nauen D, Karimi R, Viscidi R, Bord E, Batson S, Troncoso J, Koranik IJ: A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient. *Ann Neurol* 2014, 76: 140–147
 84. Nimmerjahn A, Kirchhoff F, Helmchen F: Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. *Science* 2005, 308:1314–1318
 85. Ransohoff RM, Cardona AE: The myeloid cells of the central nervous system parenchyma. *Nature* 2010, 468:253–262
 86. Grossmann R, Stence N, Carr J, Fuller L, Waite M, Dailey ME: Juxtavascular microglia migrate along brain microvessels following activation during early postnatal development. *Glia* 2002, 37: 229–240
 87. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB: ATP mediates rapid microglial response to local brain injury in vivo. *Nat Neurosci* 2005, 8:752–758
 88. Stence N, Waite M, Dailey ME: Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. *Glia* 2001, 33: 256–266
 89. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, Julius D: The P2Y₁₂ receptor regulates microglial activation by extracellular nucleotides. *Nat Neurosci* 2006, 9:1512–1519
 90. Prinz M, Priller J: Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. *Nat Rev Neurosci* 2014, 15:300–312
 91. Siebrasse EA, Nguyen NL, Smith C, Simmonds P, Wang D: Immunohistochemical detection of KI polyomavirus in lung and spleen. *Virology* 2014, 468–470:178–184
 92. Simon-Santamaria J, Rinaldo CH, Kardas P, Li R, Malovic I, Elvevold K, McCourt P, Smedsrod B, Hirsch HH, Sorensen KK: Efficient Uptake of Blood-Borne BK and JC Polyomavirus-Like Particles in Endothelial Cells of Liver Sinusoids and Renal Vasa Recta. *PLoS One* 2014, 9:e111762
 93. Reid CE, Li H, Sur G, Carmillo P, Bushnell S, Tizard R, McAuliffe M, Tonkin C, Simon K, Goelz S, Cinque P, Gorelik L, Carulli JP: Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. *J Infect Dis* 2011, 204:237–244
 94. Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P: Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. *J Infect Dis* 2011, 204:103–114
 95. Maginnis MS, Stroh LJ, Gee GV, O'Hara BA, Derdowski A, Stehle T, Atwood WJ: Progressive multifocal leukoencephalopathy-associated mutations in the JC polyomavirus capsid disrupt lactoseries tetrasaccharide c binding. *MBio* 2013, 4. e00247-13